NCT02572167 - A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 1, 2018

Study Completion Date

October 21, 2021

Conditions

Hodgkin Lymphoma

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles

DRUG

nivolumab

3 mg/kg by intravenous (IV) infusion for up to 4 cycles

Trial Locations (13)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Center - Commack, Commack

Duke University Medical Center, Durham

James Cancer Hospital / Ohio State University, Columbus

Karmanos Cancer Institute / Wayne State University, Detroit

Mayo Clinic Minnesota, Rochester

Washington University School of Medicine, St Louis

Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas

Stanford Cancer Center, Stanford

City of Hope National Medical Center, Duarte

Dana Farber Cancer Institute, Boston

University of Nebraska Medical Center, Omaha

Hackensack University Medical Center, Hackensack